Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aurisco Expands Oligonucleotide Capacity | Contract Pharma
Breaking News

Aurisco Expands Oligonucleotide Capacity

OligoPilot 2000TM solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.

Aurisco Pharmaceutical, a pharmaceutical contract research, development and manufacturing organization (CRDMO) expanded its oligonucleotide manufacturing capacity.

The new OligoPilot 2000TM solid-phase synthesizer, from Cytiva, completes Aurisco Biotech’s pilot scale cGMP plant and provides immediate capacity availability to accelerate customer’s clinical programs as well as Aurisco’s generic oligonucleotide pipeline.

Peng Zhien, chairman of Aurisco, said: “The company is committed to continuous technological innovation, such as solid-phase synthesis, chromatography, photochemistry and biocatalysis. Our strong R&D, state-of-art analytical tools, advanced manufacturing capabilities and project management experience will help our customers deliver faster, better, safer and more affordable medicines to patients around the world. We’ve joined Manufacture 2030, Energize and Ecovadis in a true commitment to sustainability and reduce the carbon footprint of pharmaceutical supply-chains. We pay special attention to ESG and Supply-Chain Security topics.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters